Advertisement
Singapore markets closed
  • Straits Times Index

    3,292.69
    +10.64 (+0.32%)
     
  • Nikkei

    38,405.66
    0.00 (0.00%)
     
  • Hang Seng

    17,763.03
    +16.12 (+0.09%)
     
  • FTSE 100

    8,144.13
    -2.90 (-0.04%)
     
  • Bitcoin USD

    60,651.84
    -3,066.66 (-4.81%)
     
  • CMC Crypto 200

    1,297.42
    -41.64 (-3.11%)
     
  • S&P 500

    5,035.69
    -80.48 (-1.57%)
     
  • Dow

    37,815.92
    -570.17 (-1.49%)
     
  • Nasdaq

    15,657.82
    -325.26 (-2.04%)
     
  • Gold

    2,302.80
    -0.10 (-0.00%)
     
  • Crude Oil

    81.39
    -0.54 (-0.66%)
     
  • 10-Yr Bond

    4.6860
    +0.0720 (+1.56%)
     
  • FTSE Bursa Malaysia

    1,575.97
    -6.69 (-0.42%)
     
  • Jakarta Composite Index

    7,234.20
    +78.41 (+1.10%)
     
  • PSE Index

    6,700.49
    -69.15 (-1.02%)
     

Monthly information on share capital and company voting rights

Cellectis Inc.
Cellectis Inc.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, April 04, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of shares
in the capital

Total number of voting rights

03/31/2024

71,953,535

77,889,229

For further information on Cellectis, please contact:

Media contact:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com

Investor Relations contacts:

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577


Attachment